Yesterday I decided to engage in a wee sortie on SAREPTA’s american Yahoo Finance message board in order to gauge the level of awareness of Summit’s DMD drug. I was surprised by the response (given the mess SRPT are currently in with the FDA approval / rejection postponed) … there was actually some polite banter with calm and collected P.I.’s who are heavily invested in Sarepta. Interestingly my straw pole suggests that some do actually have a small Summit investment but… Read More
Yes thought this trial would be more advanced unfortunately par for the course with Summit yet another trial delayed , albeit to be fair they have not given it much publicity , just as well c-diff sale not dependent on Fidaxomicin comparison data outcomes !!
As I understand it we've been told they expect the top line results from this study in Q3 now.
Also we've been told that any deal negotiations will not be waiting for this study. I assume they already have enough data to prove commercial value. The data shows Ridinilazole should be used as 1st and 2nd line treatment.
The study with Fidaxomicin is just a demonstration of their confidence that Ridinilazole can be compared to the current very best in class for efficacy as I see it. GLA
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.